Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shield Therapeutics ( (GB:STX) ) has issued an announcement.
Shield Therapeutics has confirmed that its issued share capital comprises 1,067,828,251 ordinary shares, each carrying equal voting rights and with no shares held in treasury, establishing the official share count that investors must use when calculating notifiable holdings under UK disclosure and transparency rules. The clarification of total voting rights provides greater transparency for shareholders and regulators, supporting accurate reporting of significant stakes in the company as it continues to commercialise its flagship iron deficiency treatment ACCRUFeR/FeRACCRU globally.
The most recent analyst rating on (GB:STX) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on GB:STX Stock
According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.
The overall stock score is primarily influenced by the company’s robust technical momentum and positive corporate events, which are offset by significant financial challenges and valuation concerns. The strong technical indicators and strategic corporate developments provide optimism, but financial instability remains a critical risk.
To see Spark’s full report on GB:STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics is a commercial-stage specialty pharmaceutical group focused on treating iron deficiency and iron deficiency anemia through its novel oral iron therapy ACCRUFeR/FeRACCRU (ferric maltol). The company markets ACCRUFeR in the U.S. via an exclusive collaboration with Viatris and has out-licensed FeRACCRU to partners across Europe, Asia-Pacific and North America, positioning the product as the leading branded prescription oral iron in a U.S. market estimated at $2.3 billion, with patent protection extending into the mid-2030s.
Average Trading Volume: 2,943,010
Technical Sentiment Signal: Buy
Current Market Cap: £104.6M
For detailed information about STX stock, go to TipRanks’ Stock Analysis page.